📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Anti-angiogenic compounds based on modulation of VEGF splicing

Lead Research Organisation: University of Bristol
Department Name: Physiology and Pharmacology

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
publication icon
Barratt SL (2017) Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis. in American journal of respiratory and critical care medicine

publication icon
Bates D (2018) Comprehensive Physiology

publication icon
Bates DO (2017) Pharmacology of Modulators of Alternative Splicing. in Pharmacological reviews

publication icon
Bowler E (2019) Alternative Splicing in Angiogenesis. in International journal of molecular sciences

publication icon
Bullock N (2016) Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion in Journal of Clinical Pathology

publication icon
Bullock N (2017) The many faces of SRPK1. in The Journal of pathology

publication icon
Gong L (2016) Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/ß-catenin signalling in NSCLC. in The Journal of pathology

publication icon
Kikuchi R (2019) Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. in Advances in clinical chemistry

publication icon
Legge D (2020) The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor

publication icon
Legge D (2022) The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor. in Molecular oncology

 
Description This award was used to explore whether a certain technology developed in my lab may be further developed and used for drug development, especially referring todrugs that affect growth of vessels.the market research done has given us clear durections on how to proceed.
Exploitation Route This project relates to drug development in the area of blood vessel growth. The findings may be used in the future to develop new drugs for diabetes, cancer or certain eye diseases.
Sectors Pharmaceuticals and Medical Biotechnology
 
Description Determining tissue uptake and retention of lead compounds identified for improving organ / tissue preservation and transplantation
Amount £44,952 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2019 
End 05/2020
 
Description Project grant
Amount £163,071 (GBP)
Funding ID 17/0005668 
Organisation Diabetes UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2018 
End 06/2020